JHS Svendgaard to invest Rs. 25 crore on building new manufacturing unit
The new facility is expected to generate 500-600 new jobs in the region
The new facility is expected to generate 500-600 new jobs in the region
The state-of-the-art facility is expected to be commissioned over the next three years
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
The center will deliver Certified Pre-Owned instruments restored to factory-grade standards and backed by Agilent Standard Warranty
Dr Kinha is a seasoned healthcare and diagnostics leader with over 17 years of experience across leading organisations in the diagnostics sector, with deep expertise in laboratory operations and quality systems
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
This recognition demonstrate excellence in intellectual property (IP) value creation.
The move strengthens GBL’s clinical-stage presence in the United States
The combination also outperformed chemotherapy on another important secondary endpoint
Subscribe To Our Newsletter & Stay Updated